Renalytix loss widens, revenue affected by disruption to testing

(Alliance News) - Renalytix PLC on Friday said its net loss for the three months ended March 30 ...

Alliance News 9 June, 2023 | 1:30PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Renalytix PLC on Friday said its net loss for the three months ended March 30 narrowed amid cuts in administrative costs.

The London-based kidney health-focused diagnostics company said pretax net loss for the third quarter of financial 2023 narrowed to USD12.1 million from USD14.7 million the year before, as general and administrative expenses fell by 11% to USD7.1 million.

Revenue fell 11% to USD724,000 from USD812,000 the year before. Renalytix said this related to its KidneyIntelX test, which is used to test type two diabetes and chronic kidney disease, as the transition to commercial payments for testing with Mount Sinai Healthcare had a short-term impact on testing volumes.

Looking ahead, Renalytix said it will continue working with the US Food & Drug Administration in their evaluation of a marketing application for KidneyIntelX and strengthen its balance sheet with new funding.

Shares in Renalytix were down 1.7% at 86.00 pence each in London on Friday afternoon.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Renalytix PLC 23.00 GBX -2.13 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures